Publications

Breast (Edinburgh, Scotland)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

01-08-2023

Clinical cancer research : an official journal of the American Association for Cancer Research

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer.

05-07-2023

The oncologist

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.

05-07-2023

Current treatment options in oncology

Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.

01-06-2023

NPJ breast cancer

Immune landscape of breast tumors with low and intermediate estrogen receptor expression.

13-05-2023

Oncoimmunology

Neoadjuvant immune checkpoint blockade triggers persistent and systemic T_reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors.

24-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].

01-03-2023

International journal of molecular sciences

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.

03-02-2023

Cancer cell

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

09-01-2023

Nature communications

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

21-11-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

01-11-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.

01-08-2022

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.

20-07-2022

Nature communications

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

27-06-2022

Expert opinion on investigational drugs

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.

01-06-2022

British journal of cancer

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.

01-06-2022

NPJ breast cancer

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.

28-04-2022

Nature cancer

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.

01-03-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

01-03-2022

Virchows Archiv : an international journal of pathology

Incorporation of TILs in daily breast cancer care: how much evidence can we bear?

01-01-2022

Breast care (Basel, Switzerland)

Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).

01-12-2021

NPJ breast cancer

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

01-12-2021

Science translational medicine

Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.

27-10-2021

Cancers

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.

29-09-2021

Nature communications

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.

27-09-2021

Annals of oncology : official journal of the European Society for Medical Oncology

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

01-09-2021

Annals of oncology : official journal of the European Society for Medical Oncology

'IMpassionate conflicts' in immunotherapy trials for metastatic triple-negative breast cancer.

01-08-2021

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Simultaneous analysis of E1 and E2 by LC-MS/MS in healthy volunteers: estimation of reference intervals and comparison with a conventional E2 immunoassay.

15-07-2021

Annals of oncology : official journal of the European Society for Medical Oncology

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

01-05-2021

Cancers

A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer.

16-01-2021

Key Publication

European journal of cancer (Oxford, England : 1990)

Adjuvant chemotherapy in small node-negative triple-negative breast cancer.

01-08-2020

Molecular cancer research : MCR

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

01-07-2020

NPJ breast cancer

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

22-05-2020

NPJ breast cancer

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

16-05-2020

NPJ breast cancer

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

16-05-2020

Annals of oncology : official journal of the European Society for Medical Oncology

Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.

01-05-2020

Nature medicine

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

01-04-2020

The Journal of pathology

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.

01-04-2020

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.

01-04-2020

European journal of cancer (Oxford, England : 1990)

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

01-03-2020

Breast cancer research : BCR

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.

26-12-2019

Breast cancer research : BCR

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.

07-08-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

ESMO open

How I treat MSI cancers with advanced disease.

25-06-2019

Nature medicine

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-06-2019

Insights into imaging

Cryoablation and immunotherapy: an overview of evidence on its synergy.

20-05-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

01-02-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study.

01-01-2019

Oncoimmunology

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

14-12-2018

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer.

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.

Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.

Immune landscape of breast tumors with low and intermediate estrogen receptor expression.

Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors.

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.

IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

Incorporation of TILs in daily breast cancer care: how much evidence can we bear?

Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

'IMpassionate conflicts' in immunotherapy trials for metastatic triple-negative breast cancer.

Simultaneous analysis of E1 and E2 by LC-MS/MS in healthy volunteers: estimation of reference intervals and comparison with a conventional E2 immunoassay.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer.

Adjuvant chemotherapy in small node-negative triple-negative breast cancer.

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

How I treat MSI cancers with advanced disease.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Cryoablation and immunotherapy: an overview of evidence on its synergy.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study.

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

This site uses cookies

Neoadjuvant immune checkpoint blockade triggers persistent and systemic T_reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors.

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.